SCHEMBL16636803

SCHEMBL16636803

CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)(CO)CO

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.59
PRKCE Q02156 1/20 0.57
PRKCQ Q04759 1/20 0.57
PRKCD Q05655 1/20 0.57
PRKCA P17252 1/20 0.57
MGLL Q99685 1/20 0.55
CNR2 P34972 1/20 0.54
HRH3 Q9Y5N1 1/20 0.52
TERT O14746 3/20 0.51
CYP1A2 P05177 2/20 0.51
MAPT P10636 2/20 0.51
CYP2C19 P33261 2/20 0.51
BLM P54132 2/20 0.51
HSD17B10 Q99714 2/20 0.51
FABP4 P15090 2/20 0.51
FAAH O00519 2/20 0.51
PTPN1 P18031 2/20 0.51
PPARG P37231 2/20 0.51
KMT2A Q03164 2/20 0.51
PPARD Q03181 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16308645 1.00 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL145547 1.00 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL11784673 1.00 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL9816852 0.97 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL3856010 0.97 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL29369084 0.97 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL4132279 0.97 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL10993478 0.97 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL3855244 0.97 DGKA (0.59) DGKAPRKCEPRKCQPRKCDPRKCA
SCHEMBL9248327 0.96 MGLL (0.62) DGKAMGLLCNR2MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10231985-B2 Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-03-19 US claimed
EP-3065733-B1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NAT RECH SCIENT (FR) 2018-05-30 EP claimed
EP-3065732-B1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA CENTRE NAT RECH SCIENT (FR) 2018-04-11 EP claimed
US-20160287542-A1 COMPOUNDS, COMPOSITIONS AND CORRESPONDING USES FOR PREVENTING AND/OR TREATING OF DYSLIPIDEMIA UNIVERSITE DE POITIERS (FR) 2016-10-06 US claimed
EP-3065732-A1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA Centre National de la Recherche Scientifique (CNRS) (FR) 2016-09-14 EP claimed
EP-3065733-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS Centre National De La Recherche Scientifique (FR) 2016-09-14 EP claimed
US-20160256429-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-09-08 US claimed
WO-2015052237-A1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2015-04-16 WO claimed
WO-2015052433-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-04-16 WO claimed
US-10231985-B2 Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-03-19 US disclosed
US-10156566-B2 Detoxification of microbial virulence factors in oral cavity THE PROCTER & GAMBLE COMPANY (US) 2018-12-18 US disclosed
EP-3065733-B1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NAT RECH SCIENT (FR) 2018-05-30 EP disclosed
EP-3065732-B1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA CENTRE NAT RECH SCIENT (FR) 2018-04-11 EP disclosed
US-9821000-B2 Compounds, compositions and corresponding uses for preventing and/or treating of dyslipidemia CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-11-21 US disclosed
EP-3065732-A1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA Centre National de la Recherche Scientifique (CNRS) (FR) 2016-09-14 EP disclosed
EP-3065733-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS Centre National De La Recherche Scientifique (FR) 2016-09-14 EP disclosed
US-20160256429-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-09-08 US disclosed
CN-105754696-A Anti-rust lubricating grease for pump thread hole 安徽埃斯克制泵有限公司 2016-07-13 CN disclosed
WO-2015052237-A1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2015-04-16 WO disclosed
WO-2015052433-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160287542-A1 COMPOUNDS, COMPOSITIONS AND CORRESPONDING USES FOR PREVENTING AND/OR TREATING OF DYSLIPIDEMIA LIPC, CPT1A, LIPA DGKA 1043/4885PRKCE 1347/4885PRKCQ 1822/4885
US-20160256429-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS LIPC, FABP4, PNLIP DGKA 195/4885PRKCE 641/4885PRKCQ 770/4885
US-10156566-B2 Detoxification of microbial virulence factors in oral cavity GSTM2, GSTA2, GSTA1 DGKA 2169/4885PRKCE 4078/4885PRKCQ 3681/4885
US-10231985-B2 Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias LIPC, FABP4, PNLIP DGKA 195/4885PRKCE 641/4885PRKCQ 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.